Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics signatures of circulating factors associated with cardiorespiratory fitness adaptations in individuals with prediabetes.

Cardiovascular diabetology·2026
Same author

Dermocosmetic Potential of <i>Punica granatum</i>: A Systematic Review of Bioactive Compounds and Skincare Applications.

Antioxidants (Basel, Switzerland)·2026
Same author

Consensus Document of the Spanish Nutrition Society (SEÑ) on Nutritional Strategies in Sports.

Nutrients·2025
Same author

Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.

AIDS (London, England)·2025
Same author

Sexual activity before exercise influences physiological response and sports performance in high-level trained men athletes.

Physiology & behavior·2025
Same author

Untargeted metabolomic approach to assess the acute metabolism and urinary excretion of olive leaf bioactive compounds in humans.

Food research international (Ottawa, Ont.)·2025

Related Experiment Video

Updated: May 19, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction.

Jesica Martínez-Godfrey1, Irene Pomares-Bri1, Paula de Juan-Maciá1

  • 1Instituto de Investigación en Biotecnología y Salud (IDiBE), Universidad Miguel Hernández de Elche (UMH), Elche, Spain.

Obesity Reviews : an Official Journal of the International Association for the Study of Obesity
|May 17, 2026
PubMed
Summary

Obesity is a multisystem disorder linking chronic inflammation to insulin resistance and cancer. New therapies target appetite control and metabolic pathways for effective obesity management.

Keywords:
insulin resistanceneuromodulationobesitythermogenesistumor microenvironment

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 19, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

  • Multidisciplinary review integrating metabolic, immunological, and oncological evidence.
  • Focus on obesity as a complex multisystem disorder with significant health implications.

Background:

  • Obesity, characterized by excessive adipose tissue, is a global health challenge.
  • It has profound metabolic, inflammatory, and oncogenic consequences.
  • Chronic inflammation is a key mediator linking obesity to insulin resistance, type 2 diabetes, and cancer.

Purpose of the Study:

  • To provide a multidisciplinary perspective on obesity as a multisystem disorder.
  • To review current literature on metabolic, immunological, and oncological aspects of obesity.
  • To highlight novel therapeutic strategies for obesity and related conditions.

Main Methods:

  • Narrative review of current scientific literature.
  • Integration of metabolic, immunological, and oncological evidence.
  • Examination of molecular mechanisms and therapeutic targets.

Main Results:

  • Adipose tissue dysfunction, altered adipokines, and immune cell infiltration drive obesity pathogenesis.
  • Hyperinsulinemia and dysregulated adipokines (leptin, adiponectin) influence tumor progression.
  • Therapeutic strategies include metformin, targeted receptor therapies, white adipose tissue browning, and appetite-regulating medications (GLP-1, GIP agonists).

Conclusions:

  • Obesity's complexity necessitates integrated approaches beyond traditional diet and exercise.
  • Understanding its multisystem impact is crucial for developing novel interventions.
  • Targeting inflammation, metabolic pathways, and appetite control offers promising therapeutic avenues.